bepirovirsen
Jump to navigation
Jump to search
Indications
- treatment of chronic hepatitis B infection
* sustained HBsAg & HBV DNA loss in 9- 10% of patients
Dosage
- 300 mg per week for 24 weeks
Mechanism of action
- antisense oligonucleotide that targets all hepatitis B virus messenger RNAs
- decreases levels of hepatitis B viral proteins
More general terms
- short interfering double-stranded RNA; antisense oligonucleotide (siRNA, microRNA, miRNA)
- antiviral agent
Additional terms
References
- ↑ Yuen M-F et al. Efficacy and safety of bepirovirsen in chronic hepatitis B infection. N Engl J Med 2022 Nov 8; [e-pub]. PMID: https://www.ncbi.nlm.nih.gov/pubmed/36346079 https://www.nejm.org/doi/10.1056/NEJMoa2210027
Hoofnagle JH. A modern therapy for an ancient disease. N Engl J Med 2022 Nov 8; [e-pub]. PMID: https://www.ncbi.nlm.nih.gov/pubmed/36346068 https://www.nejm.org/doi/10.1056/NEJMe2213449